GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022

GenSight Biologics Reports Full Year 2021 Consolidated Financial Results

GenSight Biologics Announces its 2022 Financial Calendar

Chardan 5th Annual Genetic Medicines Conference – virtual

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings in October

Redburn Gene Therapy Virtual Summit 2021

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update

GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France